Ultime notizie per HUTCHMED (China) (NASDAQ:HCM) Azioni

HUTCHMED (China)

HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China) Ltd

HCM ACQUISITION CORP USD CL A ORD SHS

HCM ACQUISITION CORP USD UNITS CONSISTING ONE CL A ORD SH OF $0.0001 PAR VALUE &

HCM ACQUISITION CORP USD RED WTS

HEALTHIER CHOICES MGMT by Healthier Choices Management Corp.

Healthier Choices Management Corp

Holcim Ltd

Direxion Shares ETF Trust Direxion HCM Tactical Enhanced US ETF

Consolidated Edison (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ED#NYSE">ED</a>) reported quarterly earnings of $1.68 per share which beat the analyst consensus estimate of $1.62 by 3.7 percent.

Earnings

Earnings Beats

News

Consolidated Edison Q3 2024 Adj. EPS $1.68 Beats $1.62 Estimate

PDF Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDFS#NASDAQ">PDFS</a>) reported quarterly earnings of $0.25 per share which beat the analyst consensus estimate of $0.20 by 25 percent. The company reported quarterly sales of $46.409 million which beat the analyst consensus estimate of $46.196 million by 0.46 percent. This is a 9.58 percent increase over sales of $42.350 million the same period last year.

PDFS

PDF Solutions Q3 2024 Adj. EPS $0.25 Beats $0.20 Estimate, Sales $46.409M Beat $46.196M Estimate

TELA Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELA#NASDAQ">TELA</a>) affirms FY2024 sales outlook from $74.50 million-76.50 million to $74.50 million-76.50 million.

Guidance

TELA

TELA Bio Affirms FY2024 Sales Guidance from $74.50M-76.50M to $74.50M-76.50M

Iovance Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) affirms FY2025 Product sales outlook from $450.00 million-475.00 million to $450.00 million-475.00 million.

IOVA

Iovance Biotherapeutics Affirms FY2025 Product Sales Guidance from $450.00M-475.00M to $450.00M-475.00M

Collegium Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLL#NASDAQ">COLL</a>) raises FY2024 sales outlook from $580.00 million-595.00 million to $620.00 million-635.00 million.

COLL

Collegium Pharmaceutical Raises FY2024 Sales Guidance from $580.00M-595.00M to $620.00M-635.00M  VS Est.625.37M

CPAY

Corpay Expects Q4 Total Revenues Of $1.04B - $1.07B, Adjusted EP Of $5.25 - $5.45

Iovance Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) affirms FY2024 Product sales outlook from $160.00 million-165.00 million to $160.00 million-165.00 million.

Iovance Biotherapeutics Affirms FY2024 Product Sales Guidance from $160.00M-165.00M to $160.00M-165.00M

AerSale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASLE#NASDAQ">ASLE</a>) reported quarterly earnings of $0.04 per share which missed the analyst consensus estimate of $0.05 by 20 percent. This is a 33.33 percent increase over earnings of $0.03 per share from the same period last year. The company reported quarterly sales of $82.68 million which missed the analyst consensus estimate of $92.83 million by 10.93 percent. This is a 10.60 percent decrease over sales of $92.48 million the same period last year.

Earnings Misses

ASLE

AerSale Q3 Adj $0.04 Misses $0.05 Estimate, Sales $82.68M Miss $92.83M Estimate

Amprius Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPX#NYSE">AMPX</a>) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.13) by 23.08 percent. The company reported quarterly sales of $7.855 million which beat the analyst consensus estimate of $4.215 million by 86.37 percent. This is a 180.74 percent increase over sales of $2.798 million the same period last year.

AMPX

Amprius Technologies Q3 2024 GAAP EPS $(0.10) Beats $(0.13) Estimate, Sales $7.855M Beat $4.215M Estimate

Identiv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVE#NASDAQ">INVE</a>) sees Q4 sales of $6.000 million-6.300 million vs $5.95 million estimate.

INVE

Identiv Sees Q4 Sales $6.000M-6.300M vs $5.95M Est

Fourth Quarter 2024 Outlook
For the fourth quarter 2024, the Company expects:
<ul>
<li>Revenue growth on a constant currency basis in the range of 10.3%-13.3%. This represents revenue in the range of $375-$385 million, assuming FX rates remain relatively stable with the end of Q3.&nbsp;</li>
<li>Adjusted EBITDA in the range of $9-$14 million, representing an Adjusted EBITDA Margin in the range of 2.4%-3.6%.&nbsp;</li>
</ul>

WBTN

WEBTOON Entertainment Sees Q4 Revenue Growth On A Constant Currency Basis In The Range Of 10.3%-13.3% ($375M-$385M) Vs $375.92M Est.

Tidewater Sees 2024 Revenue $1.33B-$1.35B vs $1.39B Est.

Innodata (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INOD#NASDAQ">INOD</a>) reported quarterly earnings of $0.35 per share which beat the analyst consensus estimate of $0.13 by 169.23 percent. The company reported quarterly sales of $52.224 million which beat the analyst consensus estimate of $36.113 million by 44.61 percent. This is a 135.57 percent increase over sales of $22.169 million the same period last year.

INOD

Innodata Q3 2024 Adj. EPS $0.35 Beats $0.13 Estimate, Sales $52.224M Beat $36.113M Estimate

ABNB

Airbnb Sees Q4 2024 Revenue $2.39B-$2.44B Vs $3.717B Est.

Ouster (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NYSE">OUST</a>) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.57) by 5.26 percent. This is a 39.33 percent increase over losses of $(0.89) per share from the same period last year. The company reported quarterly sales of $28.07 million which beat the analyst consensus estimate of $28.02 million by 0.20 percent. This is a 26.41 percent increase over sales of $22.21 million the same period last year.

OUST

Ouster Q3 EPS $(0.54) Beats $(0.57) Estimate, Sales $28.07M Beat $28.02M Estimate

AFRM

Affirm Sees FY25 GMV OF More Than $34B

Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.47) by 25.53 percent. This is a 1083.33 percent decrease over earnings of $0.06 per share from the same period last year. The company reported quarterly sales of $2.975 million which missed the analyst consensus estimate of $3.020 million by 1.49 percent. This is a 9.82 percent decrease over sales of $3.299 million the same period last year.

AXDX

Accelerate Diagnostics Q3 2024 GAAP EPS $(0.59) Misses $(0.47) Estimate, Sales $2.975M Miss $3.020M Estimate

Financial Outlook for Full Year 2024
The following tables summarize Getty Images' updated fiscal year 2024 guidance:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Updated 2024 Guidance</td>
<td>Prior 2024 Guidance</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Revenue</td>
<td>$934 million to $943 million</td>
<td>$924 million to $943 million</td>
</tr>
<tr>
<td>Revenue YoY</td>
<td>1.9% to 2.9%</td>
<td>0.9% to 2.9%</td>
</tr>
<tr>
<td>Revenue YoY, Currency Neutral</td>
<td>1.6% to 2.6%</td>
<td>1.0% to 3.0%</td>
</tr>
<tr>
<td>Adjusted EBITDA</td>
<td>$292 million to $294 million</td>
<td>$290 million to $294 million</td>
</tr>
<tr>
<td>Adjusted EBITDA YoY</td>
<td>(3.1)% to (2.5)%</td>
<td>(3.8)% to (2.5)%</td>
</tr>
<tr>
<td>Adjusted EBITDA YoY, Currency Neutral</td>
<td>(3.4)% to (2.8)%</td>
<td>(3.6)% to (2.3)%</td>
</tr>
</tbody>
</table>
</figure>
 Guidance has been updated to reflect the Company's financial performance year to date and the impact of foreign currency exchange rates on both Revenue and Adjusted EBITDA.

GETY

Getty Images Raises FY24 Revenue From $924M-$943M To $934M-$943M Vs $932.61M Est.

Affirm Sees Q2 Revenue $770M-$810M

Corpay Narrows FY24 Total Revenue Outlook From $3.975B - $4.025B To $3.98B - $4.01B (Est $3.989B), Adjusted EPS Forecast From $18.85 - $19.15. To $18.90 - $19.10 (Est $18.96)

Hutchison China MediTech Non-GAAP EPS of $0.50, revenue of $420M

Hutchison China MediTech GAAP ADS of $0.15, revenue of $305.68M

HUTCHMED (China) Limited 2024 Q2 - Results - Earnings Call Presentation

HUTCHMED (China) Limited (HCM) Q2 2024 Earnings Call Transcript

HUTCHMED (HCM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Paul Choi from Goldman Sachs...

Hold Rating on HUTCHMED Amid Promising U.S. Launch and Pending EU Reimbursement Clarity

HUTCHMED (China) Limited (HCM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on August 2. Analyst Jill W...

Robust Sales and Expansion Potential Underpin Buy Rating for HUTCHMED

Hutchmed Growing Sales By 64% In H1 2024

HUTCHMED pulls regulatory submission for Takeda-partnered cancer drug in China

Chinese biotechs gain as drugmakers targeted in new security bill said to mull divestments

Hutchmed (HCM) announced that new and updated data from the sovleplenib ESLIM-01 Phase III trial, as well as several investigator-initiated studies...

Hutchmed announces new, updated data from sovleplenib ESLIM-01 trial

BGNE

HMDCF

IMAB

WUXIF

WXIBF

WXXWY

ZLAB

Press Releases

HUTCHMED Reports 2024 Interim Results and Provides Business Updates

Health Care

HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia

General

HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China

HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer

International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024

Contracts

HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda

Opinion

FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket

HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial

Comments

HUTCHMED (China)

Notizie

Ultime notizie per HUTCHMED (China) (NASDAQ:HCM) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO